Prentiss Smith & Co. Inc. Has $5.47 Million Stock Position in Becton, Dickinson and Company (NYSE:BDX)

Prentiss Smith & Co. Inc. grew its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 1.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 22,701 shares of the medical instruments supplier’s stock after buying an additional 232 shares during the quarter. Becton, Dickinson and Company comprises 3.5% of Prentiss Smith & Co. Inc.’s holdings, making the stock its 9th biggest position. Prentiss Smith & Co. Inc.’s holdings in Becton, Dickinson and Company were worth $5,473,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently made changes to their positions in the company. Sound Income Strategies LLC boosted its position in shares of Becton, Dickinson and Company by 35.8% during the 3rd quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock valued at $40,000 after purchasing an additional 44 shares in the last quarter. Opal Wealth Advisors LLC acquired a new stake in shares of Becton, Dickinson and Company during the 2nd quarter valued at $45,000. Abound Wealth Management grew its holdings in shares of Becton, Dickinson and Company by 96.0% during the 2nd quarter. Abound Wealth Management now owns 196 shares of the medical instruments supplier’s stock valued at $46,000 after acquiring an additional 96 shares in the last quarter. Chilton Capital Management LLC increased its stake in shares of Becton, Dickinson and Company by 1,233.3% in the second quarter. Chilton Capital Management LLC now owns 200 shares of the medical instruments supplier’s stock worth $47,000 after acquiring an additional 185 shares during the last quarter. Finally, Tributary Capital Management LLC purchased a new stake in shares of Becton, Dickinson and Company during the first quarter worth $49,000. 86.97% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

BDX has been the subject of several recent analyst reports. Stifel Nicolaus upped their price target on Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a research note on Friday, July 26th. Citigroup raised Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and raised their target price for the company from $255.00 to $275.00 in a report on Tuesday, October 1st. StockNews.com upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Raymond James lowered their price objective on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a research note on Friday, August 2nd. Finally, Evercore ISI raised their price target on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $282.63.

Becton, Dickinson and Company Price Performance

Shares of BDX traded down $3.01 during trading hours on Monday, hitting $240.74. The stock had a trading volume of 184,516 shares, compared to its average volume of 1,388,312. The stock has a market capitalization of $69.58 billion, a price-to-earnings ratio of 53.69, a P/E/G ratio of 1.79 and a beta of 0.42. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.85 and a quick ratio of 1.36. The company’s fifty day moving average is $237.01 and its two-hundred day moving average is $235.18. Becton, Dickinson and Company has a 52 week low of $218.75 and a 52 week high of $262.23.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share for the quarter, topping the consensus estimate of $3.31 by $0.19. The company had revenue of $4.99 billion during the quarter, compared to analyst estimates of $5.08 billion. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. The company’s revenue was up 2.3% on a year-over-year basis. During the same quarter last year, the business posted $2.96 earnings per share. On average, analysts anticipate that Becton, Dickinson and Company will post 13.11 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, September 30th. Investors of record on Monday, September 9th were issued a $0.95 dividend. The ex-dividend date was Monday, September 9th. This represents a $3.80 dividend on an annualized basis and a dividend yield of 1.58%. Becton, Dickinson and Company’s dividend payout ratio is 83.70%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.